What is Jnana Therapeutics?
Jnana Therapeutics operates at the intersection of computational biology and medicinal chemistry. Its core innovation, the RAPID platform, enables the rapid discovery of small molecule therapeutics by mapping the interactions between small molecules and proteins within living cells. This approach allows the company to unlock high-value therapeutic targets that have historically been inaccessible to traditional drug discovery methods. By focusing on precision medicine and high-throughput screening, Jnana is effectively shortening the development cycle for novel treatments, positioning itself as a critical player in the next generation of pharmaceutical innovation.
How much funding has Jnana Therapeutics raised?
Jnana Therapeutics has raised a total of $207M across 3 funding rounds:
Series A
$50M
Series B
$50M
Series C
$107M
Series A (2017): $50M, investors not publicly disclosed
Series B (2021): $50M led by Versant Ventures, Avalon Ventures, AbbVie Ventures, Polaris Partners, RA Capital Management, and Pfizer Ventures
Series C (2022): $107M supported by RA Capital Management, Versant Ventures, Pfizer Ventures, Avalon Ventures, and Polaris Partners
Key Investors in Jnana Therapeutics
Versant Ventures
A global venture capital firm specializing in early-stage biotechnology, leveraging extensive pharmaceutical expertise and state-of-the-art laboratory facilities to build high-impact companies.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in life sciences, utilizing its internal TechAtlas think tank to support scientific and clinical innovation.
Avalon Ventures
A veteran venture capital firm with over 30 years of experience, dedicated to supporting disruptive ideas and fostering innovation within the life sciences and information technology sectors.
What's next for Jnana Therapeutics?
With the successful closure of its latest funding round, Jnana Therapeutics is well-positioned to transition its lead candidates into clinical trials. The strategic roadmap involves deepening its internal research capabilities while simultaneously pursuing high-value partnerships with global pharmaceutical entities. As the company continues to refine its chemoproteomics engine, the focus will shift toward validating its pipeline in human subjects and expanding its therapeutic footprint. The current capital structure provides the necessary runway to sustain long-term R&D efforts, ensuring that Jnana remains at the forefront of the small molecule revolution in biotechnology.
See full Jnana Therapeutics company page
